Last reviewed · How we verify
Placebo of Tacrolimus Ointment
Placebo of Tacrolimus Ointment is a immunosuppressant Small molecule drug developed by Glenmark Pharmaceuticals Ltd. India. It is currently in Phase 3 development for Prevention of organ rejection in transplant patients.
Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation.
Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation. Used for Prevention of organ rejection in transplant patients.
At a glance
| Generic name | Placebo of Tacrolimus Ointment |
|---|---|
| Sponsor | Glenmark Pharmaceuticals Ltd. India |
| Drug class | immunosuppressant |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting calcineurin, tacrolimus ointment reduces the production of interleukin-2, a cytokine involved in the activation and proliferation of T-cells. This results in a decrease in the immune response, which is beneficial for preventing organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in transplant patients
Common side effects
- Skin burning sensation
- Skin irritation
- Pruritus
Key clinical trials
- Topical Tacrolimus for Breast Cancer-related Lymphedema (PHASE2, PHASE3)
- Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo (PHASE1)
- Uses of Tacrolimus in Behcet Disease (NA)
- The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover (PHASE4)
- Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC (PHASE3)
- Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) (PHASE2)
- To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin) (PHASE3)
- Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Tacrolimus Ointment CI brief — competitive landscape report
- Placebo of Tacrolimus Ointment updates RSS · CI watch RSS
- Glenmark Pharmaceuticals Ltd. India portfolio CI
Frequently asked questions about Placebo of Tacrolimus Ointment
What is Placebo of Tacrolimus Ointment?
How does Placebo of Tacrolimus Ointment work?
What is Placebo of Tacrolimus Ointment used for?
Who makes Placebo of Tacrolimus Ointment?
What drug class is Placebo of Tacrolimus Ointment in?
What development phase is Placebo of Tacrolimus Ointment in?
What are the side effects of Placebo of Tacrolimus Ointment?
What does Placebo of Tacrolimus Ointment target?
Related
- Drug class: All immunosuppressant drugs
- Target: All drugs targeting calcineurin
- Manufacturer: Glenmark Pharmaceuticals Ltd. India — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of organ rejection in transplant patients
- Compare: Placebo of Tacrolimus Ointment vs similar drugs
- Pricing: Placebo of Tacrolimus Ointment cost, discount & access